Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.
May 14, 2013
Amicus Therapeutics to Present at UBS Global Healthcare Conference
May 9, 2013
Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates
View all »Events & Presentations
May 21, 2013 at 1:30 PM ET
UBS Global Healthcare Conference
May 9, 2013 at 5:00 PM ET
Amicus Therapeutics First Quarter 2013 Results Conference Call
